eMJA     The Medical Journal of Australia

Home | Issues | eMJA shop | My account | Classifieds | Contact | More... | Topics | Search   

Letters

Death and paramethoxyamphetamine — an evolving problem

Werner Jacobs
MJA 2002 177 (8): 460

To the Editor: I read with great interest the article by Byard et al,1 as well as the previous work by these authors on paramethoxyamphetamine (PMA)-related fatalities in South Australia.2 In 2001, I encountered a similar fatal "outbreak" in Belgium: six fatal cases, four of them in the Antwerp metropolitan area.3,4 Striking similarities between the Belgian and Australian fatalities include the clinical symptoms, the autopsy findings and the history of alleged "ecstasy" intake. Pure PMA tablets were found on a victim with an "xTc" logo pressed onto the surface of the tablets.3

I agree with Byard et al1 that the sudden "outbreaks" of death from PMA intoxication probably do not result from contamination during the synthesis of 3,4-methylene-dioxymethamphetamine (MDMA). In Belgium, there are strong indications that the resurgence of PMA resulted from a legal loophole. Early in 2001, PMA was encountered for the first time in the blood sample of a young girl who presented to an emergency department for alleged ecstasy intoxication. A few weeks later, the first fatal case was reported, and over a period of a few months five other fatal cases were seen.

After the first two deaths, PMA captured a lot of media attention and even evoked some political disturbance. By the end of 2001, PMA and its precursor molecule, p-methoxyphenylacetone, were placed on the list of regulated and restricted substances (and hence the unauthorised possession of these products became a criminal offence). Afterwards, no more fatalities were reported. I therefore hypothesise that illicit amphetamine manufacturers were aware of the (temporary) legal vacuum in Belgian law before the deaths occurred and substituted PMA for MDMA because PMA precursors were easier to obtain and less strictly controlled by legislation. It has been suggested in the Australian illicit drug report 1994,5 as well as by Byard et al,1 that manufacturers of PMA may have been deliberately marketing it as another drug (eg, MDMA) or may have promoted it specifically as a drug to augment the effects of MDMA. If this is the case, there may be serious implications for criminal liability, as we now know that PMA intoxication has a significantly worse clinical outcome than MDMA intoxication (including a greater likelihood of QRS-interval prolongation, extreme hyperthermia, seizures and a significantly lower score on the Glasgow Coma Scale).6

  1. Byard RW, Rodgers NG, James RA, et al. Death and paramethoxyamphetamine — an evolving problem. Med J Aust 2002; 176: 496. <PubMed> <eMJA full text>
  2. Byard RW, Gilbert J, James R, Lokan RJ. Amphetamine derivative fatalities in South Australia — is "ecstasy" the culprit? Am J Forensic Med Pathol 1998; 19: 261-265. <PubMed>
  3. Voorspoels S, Coucke V, Schepens P, Jacobs W. Paramethoxyamphetamine: first fatalities in Belgium. Bull TIAFT 2001; 31: 12-13.
  4. Voorspoels S, Coucke V, Covaci A, et al. Resurgence of a lethal drug: paramethoxyamphetamine deaths in Belgium. J Toxicol Clin Toxicol 2002; 40: 203-204. <PubMed>
  5. Australian illicit drug report 1994. Canberra: Australian Bureau of Criminal Intelligence, 1995.
  6. Ling LH, Marchant C, Buckley NA, et al. Poisoning with the recreational drug paramethoxyamphetamine ("death"). Med J Aust 2001; 174: 453-455. <PubMed> <eMJA full text>

(Received 15 Aug 2002, accepted 21 Aug 2002)

Department of Forensic Pathology, University Hospital Antwerp, Edegem, Belgium.

Werner Jacobs, MD PhD, Professor.

Correspondence: Professor Werner Jacobs, Department of Forensic Pathology, University Hospital Antwerp, Wilrijkstraat 10, B-2650 Edegem, Belgium. wjacobsATuia.ua.ac.be

Home | Issues | eMJA shop | My account | Classifieds | More... | Contact | Topics | Search

The Medical Journal of Australia    eMJA  

©The Medical Journal of Australia 2002 www.mja.com.au PRINT ISSN: 0025-729X ONLINE ISSN: 1326-5377